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Background: Owing to insufficient evidence in children, target
plasma concentrations of efavirenz are based on studies in adults.
Our analysis aimed to evaluate the pediatric therapeutic thresholds
and characterize the determinants of virological suppression in
African children.
Methods: We analyzed data from 128 African children (aged 1.7–
13.5 years) treated with efavirenz, lamivudine, and one among
abacavir, stavudine, or zidovudine, and followed up to 36 months.
Individual pharmacokinetic (PK) measures [plasma concentration 12
hours after dose (C12h), plasma concentration 24 hours after dose
(C24h), and area under the curve (AUC0-24)] were estimated using
population PK modeling. Cox multiple failure regression and multi-
variable fractional polynomials were used to investigate the risks of
unsuppressed viral load associated with efavirenz exposure and other
factors among 106 initially treatment-naive children, and likelihood
profiling was used to identify the most predictive PK thresholds.
Results: The risk of viral load .100 copies per milliliter decreased
by 42% for every 2-fold increase in efavirenz mid-dose concentra-
tion [95% confidence interval (CI): 23% to 57%; P , 0.001]. The
most predictive PK thresholds for increased risk of unsuppressed
viral load were C12h 1.12 mg/L [hazard ratio (HR): 6.14; 95% CI:
2.64 to 14.27], C24h 0.65 mg/L (HR: 6.57; 95% CI: 2.86 to 15.10),
and AUC0-24 28 mg$h/L (HR: 5.77; 95% CI: 2.28 to 14.58).
Children older than 8 years had a more than 10-fold increased risk of
virological nonsuppression (P = 0.005); among children younger
than 8 years, boys had a 5.31 times higher risk than girls (P = 0.007).
Central nervous system adverse events were infrequently reported.
Conclusions: Our analysis suggests that the minimum target C24h
and AUC0-24 could be lowered in children. Our findings should be
confirmed in a prospective pediatric trial.
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(J Acquir Immune Defic Syndr 2016;73:161–168)
INTRODUCTION
The nonnucleoside reverse transcriptase inhibitor efavir-
enz is recommended by the World Health Organization
(WHO) as part of first-line treatment for HIV-infected children
older than 3 years.1 Owing to its high potency, long half-life,
and availability of low-cost generic formulations, efavirenz
continues to be one of the most widely used antiretrovirals in
Africa and worldwide.2 The mid-dose plasma concentration
target of 1.0–4.0 mg/L derived from adult clinical monitoring
data is customarily also applied to trough concentrations.3,4 In
adults, systemic exposure below that range is associated with
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virological failure and higher exposures with central nervous
system (CNS) toxicities.3,5,6 The same target range is used in
children; however, rigorous analyses have not confirmed the
optimal therapeutic range for this age group.7–11
The main objective of a pharmacokinetic/pharmacody-
namic (PK/PD) analysis is to quantify the relationships
between drug dose, exposure, and response, identifying
factors affecting drug disposition and efficacy.4 Although
the high variability in efavirenz PK in children has been
thoroughly studied,12–15 analyses successfully relating
observed drug exposures to treatment response and detecting
other determinants of treatment failure are limited.9,10,16
Factors affecting efavirenz effectiveness have often been
investigated independently of drug concentrations with
inconclusive findings across studies8,9,17–20; similarly, the
effect of high efavirenz exposure on increased risk of CNS
adverse events (AEs) is unconfirmed in children.8,21–23
The recent results of ENCORE1,24,25 showing that the
standard 600 mg efavirenz dose can be reduced to 400 mg
daily without loss of efficacy in nonpregnant adults, have
prompted discussions on the validity of the widely accepted
efficacy thresholds of .1 mg/L, for a mid-dose interval or
trough concentration,25 and suggest that the target range used
for children should also be reevaluated. Our analysis therefore
aimed to characterize associations between systemic exposure
to efavirenz and risk of virological nonsuppression and CNS
AEs over the longer term, to identify factors affecting
virological nonsuppression independently of systemic expo-
sure, and to validate the lower boundary of the therapeutic
range for efavirenz in African children.
METHODS
Population and Study Design
As described previously,26 the Children with HIV in
Africa–Pharmacokinetics and Adherence/Acceptability of
Simple antiretroviral regimens study enrolled HIV-infected
antiretroviral therapy (ART)-naive and ART-experienced
children 13 years or younger in 4 sites in Uganda and
Zambia. Of 478 participants, 128 received efavirenz and
lamivudine combined with abacavir, stavudine, or zidovudine.
Children switched to boosted protease inhibitor–based second-
line ART for clinical or immunological failure following WHO
2010 guidelines. Samples for PK analysis were taken at week
6, week 36, and every 24 weeks thereafter. Efavirenz PK was
described previously.27 Viral load (VL) was measured retro-
spectively in stored plasma samples taken at enrollment and
weeks 48, 96, and 144, and at weeks 36, 60, 84, 108, and 132
when PK samples were taken. An undetectable VL was defined
as ,100 copies per milliliter, the lower limit of detection,
because many samples had to be diluted owing to low volumes.
Statistical Analysis
Empirical Bayesian estimates for the individual param-
eters from the previously developed population PK (POP-PK)
model were used to estimate steady-state mid-dose efavirenz
concentrations (C12h, defined as plasma concentration 12
hours after dose), trough concentrations (C24h, plasma
concentration 24 hours after dose), and AUC0-24 (area under
the curve) for each child at each included timepoint.27
Children followed for ,48 weeks were excluded from all
analyses. For a preliminary analysis, VL response was catego-
rized as suppressed (,100 copies/mL achieved within 48 weeks
of treatment initiation and maintained throughout the study),
single rebound (,100 copies/mL within 48 weeks and a single
viral rebound .100 copies/mL), multiple rebounds (,100
copies/mL within 48 weeks and multiple viral rebounds), and
never suppressed ,100 copies per milliliter. Treatment-
experienced children who were virologically suppressed at study
enrollment were analyzed separately. As multiple PK exposures
were available for each child, the geometric mean exposure value
(derived from all PK visits) for each child was compared between
groups using Kruskal–Wallis and rank sum tests. Categorical
factors were compared between groups using Fisher exact test.
The effects of PK on virological nonsuppression (.100
copies/mL) were then estimated using Cox proportional
hazards regression models (Andersen–Gill repeated outcomes
framework) with Efron approximation in R (survival pack-
age),28–31 including only VLs measured on PK sampling days
from week 36 onward in children who were treatment-naive
at enrollment. Samples taken before initial viral suppression
were excluded, unless children never suppressed during the
study. Each time interval ran from the preceding to current
VL (classified as suppressed vs nonsuppressed “event”), and
the estimated PK parameters at the current VL were applied to
the whole time interval. Nonlinearity in effect of PK
exposures was explored visually using smoothed splines,
and tested using fractional polynomials (using Stata 14.0 mfp,
StataCorp LP, College Station, TX).32 The best-fitting (lowest
Akaike Information Criterion) dichotomous threshold was
identified by profile likelihood. Because PK parameters were
estimated and not observed, we used a resimulation approach
to assess the impact of unobserved variability on selection of
the dichotomized threshold. The original data set was
resimulated 500 times introducing a normally distributed
random error on each of the exposure parameters, set to the
unexplained residual variability from the POP-PK model
(additive error 0.101 mg/L, proportional error 0.0672).27
The results were used to derive 95% confidence interval
(CI) for the threshold (2.5th and 97.5th percentile of
distribution of most predictive cutoffs from 500 runs).
For each PK exposure threshold identified in this
study and the previously proposed efficacy thresholds, we
calculated the sensitivity (proportion of samples correctly
predicted as notsuppressed), specificity (proportion of
samples correctly predicted as suppressed), accuracy (over-
all proportion of correctly predicted samples), positive
predictive value (proportion of samples with exposure
below the threshold not suppressed), and negative pre-
dictive value (proportion of samples with exposure above
the threshold that were suppressed).
Finally, we used backward elimination (exit P = 0.05,
retaining all levels of categorical factors where any were P ,
0.05) to consider the additional independent effects of covariates
on nonsuppression with associations (P , 0.2) in univariable
models. Categorical covariates included nucleoside reverse
transcriptase inhibitor backbone (abacavir, zidovudine,
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stavudine), sex, clinical site, mother as primary carer, and self-
reported missing doses in previous 4 weeks. Continuous
variables included pre-ART VL, CD4% pre-ART and at the
time of PK/VL measurement, age, weight-for-age Z-score,33
height-for-age Z-score,33 and Medication Event Monitoring
System (MEMS) adherence [proportion of days without drug
intake based on MEMS cap container openings in the interval
between previous and current measurement (truncated at a lower
limit of 0.5); the only covariate with incomplete information was
adherence; where no data was available for current interval the
previous MEMS adherence was carried forward, and if no
MEMS adherence data were available for the child (N = 19) we
imputed the median of all treatment-naïve patients]. Only 1 child
had concurrent coadministration of antituberculosis drugs, so this
factor was not considered. Nonlinear effects in continuous
variables were included using fractional polynomials (Stata
mfp). Interactions between factors included in the final model
were investigated and included if P , 0.05. The impact on PK
exposure of metabolic status based on CY2B6 516 GTj983 TC
single nucleotide polymorphisms34 was then investigated by
adding this factor into the final model.
CNS Adverse Events
Specific CNS toxicities relating to cognitive or motoric
functions were solicited at every follow-up visit (concentra-
tion, vivid dreams/nightmares, sleepiness/sleepwalking, wak-
ing at night, difficulty waking in the morning, dizziness) and
graded between 1 and 3 (mild to severe). Incidence of CNS
AEs was compared between groups using Fisher exact test.
RESULTS
In total, 128 children (14 being treatment-experienced)
received efavirenz in CHAPAS-3 and contributed a total of
1482 PK measurements from 570 PK visits, 345 with paired
VL measurements. Five children with ,48 week follow-up
were excluded from all analyses, and a further 3 children with
no paired PK-VL measurements were excluded from the Cox
model. Table 1 shows child characteristics and model-derived
PK parameters in each suppression group. Sixty-seven
percent of children (n = 73) who were treatment-naive at
enrollment achieved and maintained viral suppression ,100
copies per milliliter, 17% (n = 19) had a single episode of
TABLE 1. Demographic Characteristics and Model-Derived PK Parameters in Different Suppression Groups
Treatment-Naive at Enrollment Treatment-
Experienced
at EnrollmentSuppressed Single Rebound Multiple Rebound Never Suppressed
P*No. children 73 19 10 7 14 P†
Baseline
Age (yrs) 4.3 (3.5–4.7) 3.9 (3.6–4.5) 3.5 (3.3–3.8) 3.5 (3.2–8.5) 0.208 7.3 (5.7–8.5) ,0.001
Weight (kg) 14.0 (12.4–16.0) 14.5 (13.5–16.0) 13.4 (12.8–15.7) 12.3 (12.0–17.5) 0.513 20.1 (19.3–22.6) ,0.001
CD4% (%) 18.5 (11.0–24.0) 17.2 (7.3–22.1) 19.5 (15.5–24.5) 19.5 (10.3–19.5) 0.565 35.6 (31.4–37.8) ,0.001
CD4 (cells/mL) 707 (497–977) 648 (204–904) 684 (477–1047) 618 (201–913) 0.429 915 (807–1249) ,0.001









Sex (M/F) 29/44 10/9 8/2 4/3 0.133 9/5 0.091
Metabolic subgroup‡
EM 24 7 1 2 0.073 5 0.173
IM 28 6 8 3 6
SM 21 6 — 2 3
USM — — 1 — —
NRTI
Stavudine 23 7 5 1 0.738 5 0.908
Zidovudine 26 6 2 4 4
Abacavir 24 6 3 2 5
PK measure
AUC0-24 (mg$h/L) 57.1 (37.1–101.4) 57.8 (45.9–121.8) 46.6 (42.8–78.0) 36.8 (13.6–74.0) 0.360 77.7 (58.5–114.2) 0.142
C12h (mg/L) 2.25 (1.43–4.11) 2.22 (1.77–4.96) 1.93 (1.65–3.08) 1.40 (0.5–2.83) 0.367 3.12 (2.38–4.43) 0.155
C24h (mg/L) 1.54 (0.95–3.15) 1.43 (1.19–3.69) 1.24 (1.01–1.77) 0.76 (0.31–1.82) 0.223 2.27 (1.630–3.53) 0.123
Cmax (mg/L) 4.20 (3.03–6.28) 4.42 (3.22–6.59) 3.81 (3.24–6.99) 3.50 (1.07–5.62) 0.606 5.33 (4.70–6.66) 0.159
CL (L/h) 5.6 (3.2–7.7) 5.6 (2.4–7.3) 6.2 (5.2–7.6) 9.1 (5.9–9.2) 0.382 6.5 (4.3–8.3) 0.479
Adherence (MEMS caps)§ 1.00 (0.97–1.00) 0.98 (0.95–1.00) 0.98 (0.91–0.99) 0.87 (0.69–0.95) 0.010 0.97 (0.91–1.00) ,0.001
Presented values are number or median (IQR).
*Kruskal–Wallis or Fisher exact test comparing 4 groups of originally treatment-naive children only.
†Kruskal–Wallis or Fisher exact test comparing 5 groups including children who were treatment-experienced at enrollment.
‡EM (extensive metabolizers), 516 GGj983 TT; IM (intermediate metabolizers), 516 GGj983 TC or 516 GTj983 TT, SM (slow metabolizers), 516 TTj983 TT or 516 GTj983 TC;
USM (ultraslow metabolizers), 516 GGj983 CC.
s§Data from 104 patients (91 treatment-naive and 13 treatment-experienced at enrollment).
F, female; IQR, interquartile range; M, male; MEMS, Medication Event Monitoring System; NRTI, nucleoside reverse transcriptase inhibitor.
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viral rebound, while 15% (n = 17) had multiple viral rebounds
or never suppressed. There were no statistically significant
differences in baseline (pre-ART) demographic character-
istics or geometric mean PK parameters across study follow-
up between these 4 groups. However, there was a trend to
lower average exposures and higher average clearance among
treatment-naive children who never suppressed, compared
with children who achieved and sustained viral suppression
(pairwise rank sum: C12h P = 0.11, C24h P = 0.07, AUC P =
0.12, clearance P = 0.08). Average adherence was also
significantly lower in those who never suppressed (P =
0.004 vs sustained suppression), whereas there was no
difference in demographics between these 2 groups.
Of 14 children who were treatment-experienced (and
virologically suppressed) at enrollment, 1 had a single
episode of viral rebound, the rest remained suppressed
throughout follow-up. Children who were treatment-
experienced at enrollment differed significantly from the
treatment-naive children in baseline characteristics and had
higher geometric mean efavirenz exposures (all P , 0.05 vs
naive children combined) but no difference in average
clearance (P = 0.63). Average adherence was marginally
lower in treatment-experienced compared with the treatment-
naive patients (0.97 vs 1.00, P = 0.006).
Hazard of Virological Nonsuppression
Repeated measures Cox proportional hazards regres-
sion models fitted to 345 matched PK-VL samples from 106
treatment-naive children indicated that the risk of virological
nonsuppression increased approximately uniformly with each
fold-change in PK exposures (ie, a log transform of PK
exposure) (Table 2).
Profile likelihood identified thresholds of 1.12 mg/L
(95% CI from resimulations 0.47 to 1.56 mg/L) for C12h,
0.65 mg/L (95% CI: 0.25 to 1.27) for C24h, and 28 mg$h/L
(95% CI: 20.47 to 32.22) for AUC0-24 as the best dichotomized
thresholds for predicting virological suppression (see Supple-
mental Digital Content, http://links.lww.com/QAI/A819). For
AUC, the model including log exposure was superior,
whereas for C12h and C24h, a dichotomized threshold
provided a better model fit, but these margins were
relatively small (Table 2).
Multivariate Analysis
The 3 PK exposures were highly correlated (Spearman
rho .0.98), which could be expected because they were
derived from the same POP-PK model. We therefore only
considered C12h in multivariable models. The only other
factors associated (P , 0.2) with virological nonsuppression
in univariate analyses were sex, site, current age, and current
weight-for-age Z-score. However, only C12h, sex, site, and
current age were independent predictors (selected using
backward elimination). There was a significant interaction
between sex and age (P = 0.01), ie, age was an effect modifier
for sex. To represent this interaction, we dichotomized age at
8 years (based on univariate profile likelihood as for PK
exposures). Adjusting for other factors, the hazard of
virological nonsuppression for boys ,8 years was 5 times
greater than that for girls of similar age (Table 3). Older
children had increased risk of virological nonsuppression
compared with younger children, but there was no evidence
of a difference between boys and girls .8 years (P = 0.76).
The hazard of virological nonsuppression was significantly
higher in the smallest site, which contributed only 5 children.
There was marginal evidence that poorer MEMS adherence
independently increased the hazard of virological nonsup-
pression (P = 0.065; effects of other factors, including C12h,
were similar to Table 3). The remaining factors, including
metabolizer status (P = 0.27), did not have an effect on viral
nonsuppression (P . 0.1).
TABLE 2. Univariable Cox Proportional Hazards Regression Models for C12h, C24h, and AUC, With Lowest AIC Values Indicating
the Models Best Describing the Association With Viral Nonsuppression
Pharmacokinetic parameter
Change in Risk Per
Unit Increase in
Absolute Exposure
Change in Risk Per Doubling
of Exposure (Per Unit Increase
in Log2 Transformed Exposure)
Change in Risk Change at
Threshold for Dichotomized
Exposure Variables (Supplement 1)
C12h (mg/L)
HR (95% CI) 0.87 (0.69 to 1.10) 0.58 (0.43 to 0.77) 6.14 (2.64 to 14.27) (vs C12h .1.12 mg/L)
P 0.241 ,0.0001 ,0.0001
AIC 324.11 305.76 304.55
C24h (mg/L)
HR (95% CI) 0.86 (0.67 to 1.11) 0.60 (0.46 to 0.78) 6.57 (2.86 to 15.10) (vs. C24h .0.65 mg/L)
P 0.246 ,0.0001 ,0.0001
AIC 324.67 304.18 302.82
AUC (mg$h/L)
HR (95% CI) 0.9941 (0.9843 to 1.0040) 0.57 (0.42 to 0.76) 5.77 (2.28 to 14.58) (vs. AUC .28 mg$h/L)
P 0.247 ,0.0001 ,0.0001
AIC 324.04 305.70 307.74
Log transform was the best-fitting fractional polynomial for C24h; for C12h and AUC the best-fitting transform was inverse square root. However, the difference in AIC compared
with log transform was very small in both cases (+0.47 and +0.97) and so the log transform is presented above for comparability with C24h and ease of interpretation.
AIC, Akaike Information Criterion; HR, hazard ratio.
Bienczak et al J Acquir Immune Defic Syndr  Volume 73, Number 2, October 1, 2016
164 | www.jaids.com Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CNS Adverse Events
Despite being solicited at every follow-up visit, only 18
CNS AEs were reported in 11 children (3 problems with
concentration, 4 vivid dreams, 2 sleep walking, 2 difficulties
waking up in the mornings, 3 waking up at night, 4 dizziness;
all but one graded mild). These 11 children included 5 slow, 4
intermediate, and 2 extensive metabolizers (exact P = 0.41).
Nine children reported one of these AEs ,24 weeks after
treatment initiation. Only 2 children reported AEs on repeated
occasions (both slow metabolizers), of which only 1 had
a paired PK sample: plasma efavirenz 4 hours after dose was
45 mg/L, but the child was incorrectly receiving 600 mg
instead of a 400 mg dose.
DISCUSSION
We observed that efavirenz concentrations were related
to virological nonsuppression in African children in a non-
linear manner, a 2-fold increase in efavirenz exposure
decreased the risk of virological nonsuppression by over
40%. Some previous studies failed to detect a similar
association,7,8,35 which could be due to a number of reasons:
TABLE 3. Univariate and Multivariate Predictors of Virological Suppression
Factor
Univariate Final Multivariate Model
HR (95% CI) P HR (95% CI) P
C12h (per doubling) 0.58 (0.43 to 0.77) ,0.001 0.61 (0.50 to 0.76) ,0.001
Sex: male vs female 2.77 (1.01 to 7.64) 0.048 (See interaction below)
Current age (reference ,8 yrs) 5.45 (1.85 to 16.06) 0.002 (See interaction below)
Sex and age (reference girl ,8 yrs) Boy ,8 yr: 6.14 (2.01 to 18.77) 0.001 Boy ,8 yr: 5.31 (1.58 to 17.82) 0.007
Girl .8 yr: 16.63 (4.05 to 68.37) ,0.001 Girl .8 yr: 15.82 (2.97 to 84.27) 0.001
Boy .8 yr: 25.50 (3.37 to 193.13) 0.002 Boy .8 yr: 12.47 (1.31 to 119.08) 0.028
Site (reference S1) S2: 0.22 (0.06 to 0.77) 0.018 S2: 0.73 (0.18 to 2.88) 0.653
S3: 0.39 (0.11 to 1.38) 0.146 S3: 1.04 (0.23 to 4.82) 0.956
S4: 2.48 (0.69 to 8.99) 0.166 S4: 4.96 (1.38 to 17.79) 0.014
WAZ (per unit higher) 0.66 (0.49 to 0.88) 0.005 —
As the final multivariable model identified a significant interaction between age and sex, this interaction is also presented unadjusted for other factors in the univariable column.
Final model selected using backward elimination, see methods. Interaction between continuous age and sex (P = 0.01) dichotomized at the optimal age threshold for presentation.
HR, hazard ratio; WAZ, weight-for-age Z-score.
TABLE 4. Comparison of Efavirenz Exposure Targets and Predictors of Virological Outcome in Pediatric Studies
Reference Derived PK Targets




Starr et al21* AUC = 60–120 mg$h/mL Not analyzed Uni: (A)† log2 bCD4%, WAZ,
bVL/(B)† WAZ, bVL
57 Cox 400 (A)†
Multi: (A)† WAZ, bVL/(B)† bVL 50 (B)†
Brundage et al16 AUC .59 mg$h/mL AUC Uni: IPAM, bVL, bCD4%, WAZ 50 Cox, TSSA 400
Multi: IPAM, bVL, AUC
Hirt et al10 Cmin .1.1 mg/L Cmin, AUC Not analyzed 48 Fisher exact test 300
AUC .51 mg$h/L
Fletcher et al9 AUC .49 mg$h/mL AUC Not analyzed 50 Logistic regression 400
Janssens et al20 Not analyzed Uni: Orphan status, male gender 212 Logistic regression 400
Multi: Orphan status
Kamaya et al18‡ Not analyzed Uni: male gender, bCD4% ,5% 250 Logistic regression 400
Multi: male gender, bCD4% ,5%




C12h .1.12 mg/L C12h, Cmin, AUC Uni: male gender, age ,8 years,
site, WAZ
118 Cox 100
Cmin .0.65 mg/L Multi: male gender, age ,8 yrs
AUC .28 mg$h/L
*Target derived based on adult data.
†Two efficacy cutoffs used: (A) 400 copies per milliliter, (B) 50 copies per milliliter; bCD4%, baseline (pre-ART) CD4 percentage.
‡Patients treated with nevirapine or efavirenz; presented results relate to efavirenz only.
bVL, baseline (pre-ART) viral load; Cox, Cox proportional hazards regression; IPAM, integrated pharmacokinetic adherence measure; multi, multivariate analysis; TSSA, tree-
structured survival analysis; Uni, univariate analysis; VL, viral load; WAZ, weight-for-age Z-score.
J Acquir Immune Defic Syndr  Volume 73, Number 2, October 1, 2016 Efavirenz PK/PD in African Children
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. www.jaids.com | 165
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
their follow-up time was short, they had only a single
outcome at one time point, they were underpowered to
characterize the PK/PD relationship, or tried to simplify it
by a linearization.7,8,21 To avoid such limitations our study
analyzed a unique set of matched PK/VL longitudinal data
using Cox multiple failure regression, allowing for repeated
within-child measurements, similar to Van Leth et al36 and
Brundage et al.16 This approach enabled us to identify the
most predictive dichotomous threshold related to increased
risk of VL .100 copies per milliliter for each PK parameter
using profile likelihood, allowing for uncertainty in estimated
PK exposures by a resampling approach.
Comparing our findings with previously proposed
cutoffs (Table 5), the 1.12 mg/L threshold we obtained
for C12 h does not differ markedly in sensitivity, specificity,
or negative predictive power from the 1.0 mg/L value
proposed by Marzolini et al.3 However, our cutoffs for
C24h and AUC0-24 (0.65 mg/L and 28 mg$h/L, respectively)
are lower than previously derived targets,3,9,10,16,36 and
substantially improved specificity, accuracy and positive
predictive power, while maintaining a negative predictive
power comparable with previously suggested therapeutic
thresholds. Although our revised cutoffs require independent
validation in a prospective pediatric trial, they were determined
from the PK/PD relationship rather than using arbitrary
percentiles of PK exposure distribution.
The results of the ENCORE1 study question the validity
of a 1 mg/L efficacy threshold in adults,25 but owing to low
failure rates in the study the authors failed to detect a significant
relationship between efavirenz exposure and the virological
outcome.35 Owing to design, analytical, and population differ-
ences, our study was able to define efavirenz exposure
thresholds associated with increased risks of virological non-
suppression. Our findings should not be extrapolated to
adults. Efavirenz clearance in children is relatively higher than
that in adults, which could affect the suggested cutoffs,
especially for C24h and AUC. Furthermore, other differences
in PK or pathophysiology between those populations cannot be
excluded, and the companion drugs used in the pediatric
antiretroviral regimens are different from those used in adults.
Although the threshold we identified for C12h is not markedly
different from 1 mg/mL, our findings do not support dose
reduction in children. In our previous analysis, we reported that
the average exposures across pediatric weight bands dosed
according to the current WHO recommendations were above
that cutoff.27 However, the average exposures were signifi-
cantly affected by CYP2B6 516 G.Tj983T.C genotype, and
individuals wild type for those polymorphisms are at risk of
subtherapeutic exposures. The results of the current analysis
support modifications of the pediatric dosing recommendations
based on individual metabolic status.
Among younger children (,8 years), we found a higher
risk of virological nonsuppression in boys. Older children
(.8 years) has similarly high risk of viral nonsuppression in
both girls and boys. This phenomenon could arise from
differences in treatment adherence by age, because similar
effects were observed after adjusting for MEMS adherence.
Although the latter is an imperfect measure of adherence,
numerous studies have showed that treatment adherence
declines with decreasing levels of parental supervision over
daily drug intake in older children and adolescents.37,38 It is
less likely that different treatment adherence explains differ-
ences between younger boys and girls, in whom caregivers
supervise medication intake. Similar effects of male sex were
detected in pediatric studies by Janssens et al,20 Kamaya
et al,18 and Jittamala et al19 (Table 4).
Adherence measures are cumulative over time since
the last visit, whereas PK exposures may be influenced by
enhanced pill-taking immediately before clinic visits. In
our analysis, children who never suppressed had lower
average adherence scores and a trend to lower systemic
exposures than those who suppressed; a similar trend was
identified in the multivariate analysis. In keeping with our
findings, Brundage et al39 showed that the effect of
adherence on the hazard of virological failure was inde-
pendent of efavirenz exposure.
Children who were treatment-experienced at enrollment
were excluded from our main analysis for several reasons.
Table 5. Comparison of Previously Published Treatment Targets for Efavirenz Concentrations and AUC and Most Predictive
Thresholds Derived in This Analysis
C12h (mg/L) C24h (mg/L) AUC (mg$h/L)
Threshold 1.03 1.12 1.03 0.65 499 6022 28
HR 6.36 6.14 3.96 6.57 3.16 3.84 5.77
95% CI 2.53 to 15.96 2.64 to 14.27 1.73 to 9.03 2.86 to 15.10 1.39 to 7.16 1.56 to 9.44 2.28 to 14.58
AIC 305.35 304.55 315.07 302.82 319.86 318.12 307.74
Samples not sup/sup (n) ,T .T ,T .T ,T .T ,T .T ,T .T ,T .T ,T .T
17/27 21/281 19/34 19/274 21/66 17/242 19/32 19/276 24/101 14/207 30/153 8/155 18/32 20/276
Sensitivity, % 44.7 50.0 55.3 50.0 63.2 78.9 44.74
Specificity, % 91.2 88.9 78.5 89.6 67.1 50.2 90.23
Accuracy, % 86.1 84.7 76.0 85.3 66.8 53.5 85.2
Positive predictive value, % 38.6 35.8 24.1 37.3 19.2 16.4 36.17
Negative predictive value, % 93.0 93.5 93.4 93.5 95.1 95.1 92.95
In gray: cutoffs proposed by this analysis, in white: previously published cutoffs.
AIC, Akaike information criterion; HR, hazard ratio; sup, suppressed; T, cutoff target.
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Inclusion criteria required these children to have been on
effective antiretroviral treatment for .2 years and have
suppressed VL. It is possible that they therefore had better
adherence or were infected with HIV strains free of non-
nucleoside reverse transcriptase inhibitor resistance mutations
(no pre-ART genotypes were available). They also differed
significantly from treatment-naive children by being older and
healthier. Interestingly, their PK exposures tended to be
higher, supporting a selection effect whereby those with
optimal viral suppression are more likely to have higher
exposure. All the matched PK/VL samples for this group of
children were suppressed, and so we could not estimate the
subsequent hazard of virological nonsuppression.
Our study has several limitations. Most important is the
risk of overfitting the current data when estimating a dichot-
omized efficacy threshold, with lower external generalizabil-
ity, which we were unable to test in a validation data set. The
proposed thresholds should also be interpreted in terms of
treatment effectiveness in the clinical setting of our study
population; their value may be lower in a setting of complete
treatment adherence. Adherence in our study was measured
only in certain time periods, and participants did not use
MEMS caps throughout the trial. This intermittent assessment
could introduce error into adherence measurement, subse-
quently affecting the estimated effect of adherence on the risk
of nonsuppression. Moreover, the wide CIs for efavirenz
exposure thresholds predicting a detectable VL show that
larger studies are needed to define thresholds more precisely.
We had no VL data between treatment start and week 36 and
therefore could not examine factors affecting time to first
suppression, or the impact of PK parameters on VL decline.
Furthermore, VL was measured on average only every 24
weeks, so our analysis assumes that no viral rebounds
occurred between scheduled measurements.
Despite major concerns, very little CNS toxicity was
reported in these predominantly younger children, although
this may be more important in adolescents.40 The relationship
between high efavirenz exposures and CNS side effects
detected in adults still remains unclear in children.8,21–23
Last, antiretroviral therapy consists of a combination of
drugs and its efficacy depends on all the components of the
tested regimen. Children in CHAPAS-3 were treated with
efavirenz and a nucleoside reverse transcriptase inhibitor
backbone consisting of lamivudine combined with either
abacavir, stavudine, or zidovudine.26 Our findings might not
be generalizable to different drug combinations, for example,
those including more effective companion drugs such as
tenofovir, although this is still rarely used in children because
of concerns about its impact on growth.
CONCLUSIONS
Efavirenz exposure predicts virological outcome, inde-
pendently of other factors, including adherence, with every 2-
fold increase in efavirenz concentration reducing the hazard
of nonsuppression by about 40%. The widely accepted lower
therapeutic threshold of 1 mg/L for mid-dose concentrations
derived in adults is applicable in children, but the cutoffs for
trough concentration and AUC0-24 could be lowered to 0.65
mg/L and 28 mg$h/L, respectively. Our findings should be
confirmed in a prospective pediatric trial.
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